Research programme: antibody therapeutics - Argenx

Latest Information Update: 22 Apr 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

22 Apr 2021 Research programme: antibody therapeutics - Argenx is available for licensing as of 22 Apr 2021. https://www.argenx.com/innovation#partnering-opportunities
12 Apr 2021 FairJourney Biologics enters into a collaboration with argenx to leverage IONTAS’ mammalian display technology to develop antibody therapeutics for Immunological disorders
12 Apr 2021 Early research in Immunological disorders in Netherlands (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com